SMILES
stringlengths 2
1.49k
| Question
stringlengths 40
251
| Answer
stringlengths 1
191
|
|---|---|---|
COS(=O)(=O)[O-].C[N+]1(C)CCN(CC(O)(c2ccccc2)C2CCCCC2)CC1 | Is this molecule characterized by a small molecular structure or a protein sequence? | It has a small molecule structure. |
COS(=O)(=O)[O-].C[N+]1(C)CCN(CC(O)(c2ccccc2)C2CCCCC2)CC1 | Please provide a description of this drug's mechanism of action. | Muscarinic acetylcholine receptor M1 antagonist |
COS(=O)(=O)[O-].C[N+]1(C)CCN(CC(O)(c2ccccc2)C2CCCCC2)CC1 | Determine if this molecule is inorganic, meaning it contains only metal atoms and fewer than two carbon atoms. | No |
COS(=O)(=O)[O-].C[N+]1(C)CCN(CC(O)(c2ccccc2)C2CCCCC2)CC1 | What is the highest development stage achieved for this compound across all indications? Please respond with Approved, Phase 3 Clinical Trials, Phase 2 Clinical Trials, Phase 1 Clinical Trials, Early Phase 1 Clinical Trials, or Clinical Phase Unknown. | Approved |
COS(=O)(=O)[O-].C[N+]1(C)CCN(CC(O)(c2ccccc2)C2CCCCC2)CC1 | Is there a black box warning associated with this drug? | No |
COS(=O)(=O)[O-].C[N+]1(C)CCN(CC(O)(c2ccccc2)C2CCCCC2)CC1 | Is it known if this drug is the first approved in its class, regardless of the indication or route of administration, acting on a specific target? | No |
COS(=O)(=O)[O-].C[N+]1(C)CCN(CC(O)(c2ccccc2)C2CCCCC2)CC1 | Is this drug used for therapeutic purposes, rather than for imaging, additives, or other non-therapeutic applications? | Yes |
COS(=O)(=O)[O-].C[N+]1(C)CCN(CC(O)(c2ccccc2)C2CCCCC2)CC1 | What is the definition of this compound's USAN stem? | quaternary ammonium derivatives |
COS(=O)(=O)[O-].C[N+]1(C)CCN(CC(O)(c2ccccc2)C2CCCCC2)CC1 | Has this approved drug been withdrawn due to toxicity reasons for all indications, populations, and doses in at least one country (not necessarily the US)? | No |
COS(=O)(=O)[O-].C[N+]1(C)CCN(CC(O)(c2ccccc2)C2CCCCC2)CC1 | How many violations of Lipinski's Rule of Five (using HBA and HBD definitions) are there for this compound? | 0 |
COS(=O)(=O)[O-].C[N+]1(C)CCN(CC(O)(c2ccccc2)C2CCCCC2)CC1 | How many aromatic rings does this compound have? | 1 |
COS(=O)(=O)[O-].C[N+]1(C)CCN(CC(O)(c2ccccc2)C2CCCCC2)CC1 | Is this compound an acid, a base, or neutral? | NEUTRAL |
COS(=O)(=O)[O-].C[N+]1(C)CCN(CC(O)(c2ccccc2)C2CCCCC2)CC1 | What is the molecular weight of this compound's parent molecule? | 317.5 |
COS(=O)(=O)[O-].C[N+]1(C)CCN(CC(O)(c2ccccc2)C2CCCCC2)CC1 | How many heavy (non-hydrogen) atoms does this compound have? | 23 |
COS(=O)(=O)[O-].C[N+]1(C)CCN(CC(O)(c2ccccc2)C2CCCCC2)CC1 | What is the first recorded year of approval for this drug? | 1982 |
COS(=O)(=O)[O-].C[N+]1(C)CCN(CC(O)(c2ccccc2)C2CCCCC2)CC1 | Is it known whether this drug is taken orally? | Yes |
COS(=O)(=O)[O-].C[N+]1(C)CCN(CC(O)(c2ccccc2)C2CCCCC2)CC1 | How many hydrogen bond acceptors does this compound have? | 2 |
COS(=O)(=O)[O-].C[N+]1(C)CCN(CC(O)(c2ccccc2)C2CCCCC2)CC1 | Is the drug administered in this specific form, such as a particular salt? | Yes |
COS(=O)(=O)[O-].C[N+]1(C)CCN(CC(O)(c2ccccc2)C2CCCCC2)CC1 | Determine if this compound is a prodrug. | No |
COS(=O)(=O)[O-].C[N+]1(C)CCN(CC(O)(c2ccccc2)C2CCCCC2)CC1 | Please provide a description of this drug's mechanism of action. | Muscarinic acetylcholine receptor M3 antagonist |
COS(=O)(=O)[O-].C[N+]1(C)CCN(CC(O)(c2ccccc2)C2CCCCC2)CC1 | How many hydrogen bond donors does this compound have? | 1 |
COS(=O)(=O)[O-].C[N+]1(C)CCN(CC(O)(c2ccccc2)C2CCCCC2)CC1 | Which USAN substem can this drug or clinical candidate name be matched with? | -ium |
COS(=O)(=O)[O-].C[N+]1(C)CCN(CC(O)(c2ccccc2)C2CCCCC2)CC1 | What is the classification of this molecule? Please respond with Small Molecule, Protein, Antibody, Oligosaccharide, Oligonucleotide, Cell, Enzyme, Gene, or Unknown. | Small molecule |
COS(=O)(=O)[O-].C[N+]1(C)CCN(CC(O)(c2ccccc2)C2CCCCC2)CC1 | What is the calculated ALogP value for this compound? | 2.85 |
COS(=O)(=O)[O-].C[N+]1(C)CCN(CC(O)(c2ccccc2)C2CCCCC2)CC1 | What is the molecular formula of this compound, including any salt that it may have? | C21H36N2O5S |
COS(=O)(=O)[O-].C[N+]1(C)CCC(=C(c2ccccc2)c2ccccc2)CC1 | Determine the type of availability for this drug. | discontinued |
COS(=O)(=O)[O-].C[N+]1(C)CCC(=C(c2ccccc2)c2ccccc2)CC1 | Determine if this drug is administered as a racemic mixture, a single stereoisomer, an achiral molecule, or has an unknown chirality. | An achiral molecule |
COS(=O)(=O)[O-].C[N+]1(C)CCC(=C(c2ccccc2)c2ccccc2)CC1 | Does this compound satisfy the rule-of-three criteria? | No |
COS(=O)(=O)[O-].C[N+]1(C)CCC(=C(c2ccccc2)c2ccccc2)CC1 | How many violations of Lipinski's Rule of Five are there for this compound, using the HBA_LIPINSKI and HBD_LIPINSKI counts? | 0 |
COS(=O)(=O)[O-].C[N+]1(C)CCC(=C(c2ccccc2)c2ccccc2)CC1 | Is it known whether this drug is administered parenterally? | No |
COS(=O)(=O)[O-].C[N+]1(C)CCC(=C(c2ccccc2)c2ccccc2)CC1 | Is it known whether this drug is applied topically? | No |
COS(=O)(=O)[O-].C[N+]1(C)CCC(=C(c2ccccc2)c2ccccc2)CC1 | What is the molecular formula of this compound, including any salt that it may have? | C21H27NO4S |
COS(=O)(=O)[O-].C[N+]1(C)CCC(=C(c2ccccc2)c2ccccc2)CC1 | What is the polar surface area (PSA) value of this compound? | 0 |
COS(=O)(=O)[O-].C[N+]1(C)CCC(=C(c2ccccc2)c2ccccc2)CC1 | Is this compound a small molecule polymer, such as polystyrene sulfonate? | No |
COS(=O)(=O)[O-].C[N+]1(C)CCC(=C(c2ccccc2)c2ccccc2)CC1 | What is the molecular weight of this compound's parent molecule? | 278.42 |
COS(=O)(=O)[O-].C[N+]1(C)CCC(=C(c2ccccc2)c2ccccc2)CC1 | Is this molecule characterized by a small molecular structure or a protein sequence? | It has a small molecule structure. |
COS(=O)(=O)[O-].C[N+]1(C)CCC(=C(c2ccccc2)c2ccccc2)CC1 | Please provide a description of this drug's mechanism of action. | Muscarinic acetylcholine receptor M1 antagonist |
COS(=O)(=O)[O-].C[N+]1(C)CCC(=C(c2ccccc2)c2ccccc2)CC1 | Determine if this molecule is inorganic, meaning it contains only metal atoms and fewer than two carbon atoms. | No |
COS(=O)(=O)[O-].C[N+]1(C)CCC(=C(c2ccccc2)c2ccccc2)CC1 | What is the highest development stage achieved for this compound across all indications? Please respond with Approved, Phase 3 Clinical Trials, Phase 2 Clinical Trials, Phase 1 Clinical Trials, Early Phase 1 Clinical Trials, or Clinical Phase Unknown. | Approved |
COS(=O)(=O)[O-].C[N+]1(C)CCC(=C(c2ccccc2)c2ccccc2)CC1 | How many hydrogen bond donors does this compound have? | 0 |
COS(=O)(=O)[O-].C[N+]1(C)CCC(=C(c2ccccc2)c2ccccc2)CC1 | Is there a black box warning associated with this drug? | No |
COS(=O)(=O)[O-].C[N+]1(C)CCC(=C(c2ccccc2)c2ccccc2)CC1 | How many heavy (non-hydrogen) atoms does this compound have? | 21 |
COS(=O)(=O)[O-].C[N+]1(C)CCC(=C(c2ccccc2)c2ccccc2)CC1 | How many aromatic rings does this compound have? | 2 |
COS(=O)(=O)[O-].C[N+]1(C)CCC(=C(c2ccccc2)c2ccccc2)CC1 | Is it known if this drug is the first approved in its class, regardless of the indication or route of administration, acting on a specific target? | No |
COS(=O)(=O)[O-].C[N+]1(C)CCC(=C(c2ccccc2)c2ccccc2)CC1 | What is the calculated ALogP value for this compound? | 4.36 |
COS(=O)(=O)[O-].C[N+]1(C)CCC(=C(c2ccccc2)c2ccccc2)CC1 | How many hydrogen bond acceptors does this compound have? | 0 |
COS(=O)(=O)[O-].C[N+]1(C)CCC(=C(c2ccccc2)c2ccccc2)CC1 | How many hydrogen bond donors are there in this compound, calculated according to Lipinski's original rules (i.e., counting NH and OH groups)? | 0 |
COS(=O)(=O)[O-].C[N+]1(C)CCC(=C(c2ccccc2)c2ccccc2)CC1 | Is this drug used for therapeutic purposes, rather than for imaging, additives, or other non-therapeutic applications? | Yes |
COS(=O)(=O)[O-].C[N+]1(C)CCC(=C(c2ccccc2)c2ccccc2)CC1 | Has this approved drug been withdrawn due to toxicity reasons for all indications, populations, and doses in at least one country (not necessarily the US)? | No |
COS(=O)(=O)[O-].C[N+]1(C)CCC(=C(c2ccccc2)c2ccccc2)CC1 | How many violations of Lipinski's Rule of Five (using HBA and HBD definitions) are there for this compound? | 0 |
COS(=O)(=O)[O-].C[N+]1(C)CCC(=C(c2ccccc2)c2ccccc2)CC1 | How many rotatable bonds does this compound have? | 2 |
COS(=O)(=O)[O-].C[N+]1(C)CCC(=C(c2ccccc2)c2ccccc2)CC1 | What is the first recorded year of approval for this drug? | 1982 |
COS(=O)(=O)[O-].C[N+]1(C)CCC(=C(c2ccccc2)c2ccccc2)CC1 | How many hydrogen bond acceptors are there in this compound, calculated according to Lipinski's original rules (i.e., counting N and O atoms)? | 1 |
COS(=O)(=O)[O-].C[N+]1(C)CCC(=C(c2ccccc2)c2ccccc2)CC1 | Is it known whether this drug is taken orally? | Yes |
COS(=O)(=O)[O-].C[N+]1(C)CCC(=C(c2ccccc2)c2ccccc2)CC1 | Is the drug administered in this specific form, such as a particular salt? | Yes |
COS(=O)(=O)[O-].C[N+]1(C)CCC(=C(c2ccccc2)c2ccccc2)CC1 | Determine if this compound is a prodrug. | No |
COS(=O)(=O)[O-].C[N+]1(C)CCC(=C(c2ccccc2)c2ccccc2)CC1 | Please provide a description of this drug's mechanism of action. | Muscarinic acetylcholine receptor M3 antagonist |
COS(=O)(=O)[O-].C[N+]1(C)CCC(=C(c2ccccc2)c2ccccc2)CC1 | What is the classification of this molecule? Please respond with Small Molecule, Protein, Antibody, Oligosaccharide, Oligonucleotide, Cell, Enzyme, Gene, or Unknown. | Small molecule |
CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1.Cl | How many aromatic rings does this compound have? | 0 |
CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1.Cl | Determine if this drug is administered as a racemic mixture, a single stereoisomer, an achiral molecule, or has an unknown chirality. | An achiral molecule |
CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1.Cl | How many rotatable bonds does this compound have? | 7 |
CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1.Cl | Does this compound satisfy the rule-of-three criteria? | No |
CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1.Cl | How many hydrogen bond acceptors are there in this compound, calculated according to Lipinski's original rules (i.e., counting N and O atoms)? | 3 |
CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1.Cl | How many violations of Lipinski's Rule of Five are there for this compound, using the HBA_LIPINSKI and HBD_LIPINSKI counts? | 0 |
CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1.Cl | Is it known whether this drug is applied topically? | No |
CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1.Cl | What is the molecular formula of this compound, including any salt that it may have? | C19H36ClNO2 |
CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1.Cl | Is this compound a small molecule polymer, such as polystyrene sulfonate? | No |
CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1.Cl | Is this molecule characterized by a small molecular structure or a protein sequence? | It has a small molecule structure. |
CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1.Cl | What is the first recorded year of approval for this drug? | 1950 |
CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1.Cl | Is it known whether this drug is administered parenterally? | Yes |
CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1.Cl | Please provide a description of this drug's mechanism of action. | Muscarinic acetylcholine receptor M1 antagonist |
CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1.Cl | Determine if this molecule is inorganic, meaning it contains only metal atoms and fewer than two carbon atoms. | No |
CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1.Cl | What is the highest development stage achieved for this compound across all indications? Please respond with Approved, Phase 3 Clinical Trials, Phase 2 Clinical Trials, Phase 1 Clinical Trials, Early Phase 1 Clinical Trials, or Clinical Phase Unknown. | Approved |
CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1.Cl | How many hydrogen bond donors does this compound have? | 0 |
CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1.Cl | Is there a black box warning associated with this drug? | No |
CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1.Cl | Is it known if this drug is the first approved in its class, regardless of the indication or route of administration, acting on a specific target? | No |
CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1.Cl | How many hydrogen bond acceptors does this compound have? | 3 |
CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1.Cl | How many hydrogen bond donors are there in this compound, calculated according to Lipinski's original rules (i.e., counting NH and OH groups)? | 0 |
CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1.Cl | Is this drug used for therapeutic purposes, rather than for imaging, additives, or other non-therapeutic applications? | Yes |
CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1.Cl | What is the polar surface area (PSA) value of this compound? | 29.54 |
CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1.Cl | Has this approved drug been withdrawn due to toxicity reasons for all indications, populations, and doses in at least one country (not necessarily the US)? | No |
CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1.Cl | How many violations of Lipinski's Rule of Five (using HBA and HBD definitions) are there for this compound? | 0 |
CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1.Cl | Determine the type of availability for this drug. | prescription only |
CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1.Cl | What is the molecular weight of this compound's parent molecule? | 309.49 |
CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1.Cl | Is this compound an acid, a base, or neutral? | BASE |
CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1.Cl | Is it known whether this drug is taken orally? | Yes |
CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1.Cl | Is the drug administered in this specific form, such as a particular salt? | Yes |
CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1.Cl | Determine if this compound is a prodrug. | No |
CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1.Cl | Please provide a description of this drug's mechanism of action. | Muscarinic acetylcholine receptor M3 antagonist |
CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1.Cl | What is the calculated ALogP value for this compound? | 4.4 |
CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1.Cl | What is the classification of this molecule? Please respond with Small Molecule, Protein, Antibody, Oligosaccharide, Oligonucleotide, Cell, Enzyme, Gene, or Unknown. | Small molecule |
CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1.Cl | How many heavy (non-hydrogen) atoms does this compound have? | 22 |
CC(C[N+](C)(C)C)OC(N)=O.[Cl-] | How many aromatic rings does this compound have? | 0 |
CC(C[N+](C)(C)C)OC(N)=O.[Cl-] | What is the molecular formula of this compound, including any salt that it may have? | C7H17ClN2O2 |
CC(C[N+](C)(C)C)OC(N)=O.[Cl-] | How many violations of Lipinski's Rule of Five are there for this compound, using the HBA_LIPINSKI and HBD_LIPINSKI counts? | 0 |
CC(C[N+](C)(C)C)OC(N)=O.[Cl-] | Determine if this drug is administered as a racemic mixture, a single stereoisomer, an achiral molecule, or has an unknown chirality. | Racemic mixture |
CC(C[N+](C)(C)C)OC(N)=O.[Cl-] | Is it known whether this drug is applied topically? | No |
CC(C[N+](C)(C)C)OC(N)=O.[Cl-] | Is this compound a small molecule polymer, such as polystyrene sulfonate? | No |
CC(C[N+](C)(C)C)OC(N)=O.[Cl-] | Is this molecule characterized by a small molecular structure or a protein sequence? | It has a small molecule structure. |
CC(C[N+](C)(C)C)OC(N)=O.[Cl-] | Please provide a description of this drug's mechanism of action. | Muscarinic acetylcholine receptor M2 agonist |